Recently, Lepu Medical announced that it intends to use its own funds of 194 million yuan to participate in the investment and establishment of professional institutions and senior investors jointly supported by the Economic and Technological Market Development Center of Beijing Economic and Information Technology Commission and Changping District. Managed industry M&A fund “Lop Ginkgo Medical Health M&A Fundâ€.
It is reported that the fund, as a cooperative sub-fund of Beijing Gaojingjian Industrial Development Fund, has been officially approved by the Beijing Gaojingjian Industrial Development Fund Joint Meeting of the Beijing Economic and Information Committee. The total fundraising size of the fund is not more than RMB 1 billion.
The announcement shows that the Lepu Ginkgo Medical Health M&A Fund is organized as a limited partnership. Each partner is funded in cash for a period of 8 years, including an investment period of 4 years and an exit period of 4 years. It is funded by the Technology Market Center of the Credit Committee. 250 million yuan, Lepu Medical invested 190 million yuan, and the rest of the funds were raised to the society, focusing on a new generation of health care and services represented by biopharmaceuticals, high-performance medical devices, precision medical care and innovative medical service models. Investment in high-quality enterprises such as cardiovascular and other medical care related to chronic diseases. Among them, Qiwo Medical Health Investment Management (Beijing) Co., Ltd. (provisional name, subject to the final approved registration name of the industrial and commercial administration department) as the fund's general partner and fund manager (GP), invested 10 million yuan. Qiwo Medical Health Investment Management (Beijing) Co., Ltd. was established by Qingqi Ginkgo Venture Capital Management (Beijing) Co., Ltd. with 51%, natural person Jinming with 29%, and Lepu Medical with 20% (investment of RMB 4 million).
Fund structure
According to the announcement, by participating in the investment of the fund, the company can leverage the fund's professional investment management team and its advanced investment management experience to enhance the company's M&A capabilities in the domestic and international healthcare sector, and to leverage and leverage the strengths of the parties to find compliance with the company's development. The strategic investment target, through the merger and reorganization of high-tech enterprises at home and abroad, enhance the core competitiveness of enterprises, optimize the allocation of industry resources, and promote the integration and upgrading of high-tech industries.
Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com